期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胆管癌EGFR信号通路与靶向治疗的关系

EGFR signaling pathway and targeted therapy for cholangiocarcinoma
下载PDF
导出
摘要 胆管癌早期诊断困难,预后差.表皮生长因子受体(epidermal growth factor receptor,EGFR)的过表达在恶性肿瘤的演进中起重要作用.以EGFR为靶点进行靶向治疗已成为肿瘤治疗的热点,研究人员已开发出针对EGFR家族的一些抗体及抑制剂,并进行细胞学实验及临床试验,取得了初步效果.目前用于EGFR靶向性治疗肿瘤的药物主要分为两类:EGFR单克隆抗体和小分子酪氨酸激酶拮抗剂.这些EGFR靶向性治疗药物在胆管癌方面的研究,主要限于体外实验阶段,临床仅有极少量试验性报道.因此,综合阐述胆管癌EGFR信号通路、对其有效的靶向治疗方法及k-ras等基因的状况对于EGFR靶向治疗和胆管癌预后的影响,对于发展胆管癌治疗的新方向、深入胆管癌临床治疗的研究具有十分重要的意义. Cholangiocarcinoma has a poor prognosis and is difficult to detect in early stage. Overexpres- sion of epidermal growth factor receptor （EGFR） plays an important role in the evolution of malignant tumors, and EGFR-targeted therapy has become a hotspot in cancer treatment. Various monoclonal antibodies and small molecule tyrosine kinase inhibitors targeting EGFR have been developed. Currently, there have been only very few reported clinical trials that assessed the efficacy of EGFR-targeted drugs in the management of cholangiocarcinoma. A comprehensive description of the EGFR signaling pathway and EGFR-targeted treatment for cholangiocarcinoma has great significance for the treatment of this malignancy.
作者 杨梓琪 樊利芳
机构地区 武汉大学基础医学院病理教研室
出处 《世界华人消化杂志》 CAS 北大核心 2013年第6期514-520,共7页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 No.81000987~~
关键词 胆管癌 表皮生长因子受体信号通路 K-RAS 西妥昔 酪氨酸酶抑制剂 靶向治疗 Cholangiocarcinoma EGFR signaling pathway k-ras Cetuximab Tyrosine kinase inhibi-tors Targeted therapy
分类号 R735.8 [医药卫生—肿瘤]
  • 相关文献

参考文献51

  • 1Khan SA, Thomas HC, Davidson BR, Taylor- Robinson SD. Cholangiocarcinoma. Lancet ,2005; 366:1303-1314 [PMID: 16214602 DOI: 10.1016/ S0140-6736 (05) 67530-7].
  • 2Shaib Y, E1-Serag HB The epidemiology of chol- angiocarcinoma. Semin Liver Dis ,2004; 24:115-125 [PMID: 15,192785 DOI: 10.1055/s-,2004-828889].
  • 3Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology ,2001; 33:1353-1357 [PM1D: 11391522 DOI: 10.1053/jhep.,2001.25087].
  • 4Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pan- creatic tumours. J Hepatol ,2002; 37:806-813 [PMID: 12445422 DOI: 10.1016/S0168-8278(02)00297-0].
  • 5Shaib YH, E1-Serag HB, Davila JA, Morgan R, McG- lynn KA. Risk factors of intrahepatic cholangiocar- cinoma in the United States: a case-control study. Gastroenterology ,2005; 128:6,20-626 [PMID: 15765398 DOI: 10.1053/j.gastro.,2004.12.048].
  • 6Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase In mortality rates from intra- hepatic cholangiocarcinoma in England and Wales ,1968-,1998. Gut ,2001; 48:816-8,20 [PMID: 11358902 DOI: 10.1136/gut.48.6.816].
  • 7Berthiaume EP, Wands J. The molecular patho- genesis of cholangiocarcinoma. Semin Liver Dis ,2004; 24:127-137 [PMID: 15,192786 DOI: 10.1055/ s-,2004-828890].
  • 8Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treat- ment of cancer. J Clin Oncol ,2003; 21:2787-2799 [PMID: 12860957 DOI: 10.1,200/JCO.,2003.01.504].
  • 9Lemmon MA. The EGF receptor family as therapeu- tic targets in breast cancer. Breast Dis ,2003; 18:33-43 [PMID: 15687687].
  • 10Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Ro- gler G. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer ,2010; 10:302 [PMID: ,20565817 DOI: 10.1186/1471-2407-10-302].

二级参考文献67

  • 1WeiGuo NaWang Yi-MinWang YanLi Deng-GuiWen Zhi-FengChen Yu-TongHe Jian-HuiZhang.Interleukin-10 -1082 promoter polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high-incidence region of north China[J].World Journal of Gastroenterology,2005,11(6):858-862. 被引量：25
  • 2Yarden Y,Sliwkowski MX.Untangling the ErbB signalling network[J].Nat Rev Mol Cell Biol,2001,2(2):127-1237.
  • 3Olayioye MA,Neve RM,Lane HA,et al.The ErbB signaling network:receptor heterodimerization in development and cancer[J].EMBO J,2000,19(13):3159-3167.
  • 4Leone F,Cavailoni G,Pignochino Y,et al.Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma[J].Clin Cancer Res,2006,12(6):1680-1685.
  • 5Grünwald V,Hidalgo M.Developing inhibitors of the epidermal growth factor receptor for cancer treatment[J].J Natl Cancer Inst,2003,95(12):851-867.
  • 6Dannenberg AJ,Lippman SM,Mann JR,et al.Cyclooxygenase-2 and epidermal growth factor receptor:,pharmacologic targets for chemoprevention[J].J Clin Oncol,2005,23(2):254-266.
  • 7Khan SA,Thomas HC,Davidson BR,et al.Cholangiocarcinoma[J].Lancet,2005,366(9493):1303-1314.
  • 8Sawyers C.Targeted cancer therapy[J].Nature,2004,432(7015):294-297.
  • 9Prescott SM,Fitzpatrick FA.Cyclooxygenase-2 and carcinogenesis[J].Biochim Biophys Acta,2000,1470(2):M69-M78.
  • 10Hayashi N,Yamamoto H,Hiraoka N,et al.Differential expression of cyclooxygenase-2(COX-2)in human bile duct epithelial cells and bile duct neoplasm[J].Hepatology,2001,34(4 Pt 1):638-650.

共引文献23

世界华人消化杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部